Immune cell army targets Hard-to-Treat throat cancer

NCT ID NCT05587543

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests whether specially engineered immune cells (CAR-T and TCR-T) can safely fight Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma that has returned or not responded to treatment. About 24 adults will receive one of two types of cell therapy, with doses increased gradually to find the safest and most effective level. The main goals are to check for side effects and see if the treatment can control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR-T cells and TCR-T cells (engineered immune cells targeting EBV)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat nasopharyngeal cancer that has come back or not responded to standard therapy.
What could go wrong: This is a very early (Phase 1) trial with only 24 participants, so it is primarily testing safety and dosing. The therapy may not shrink tumors, and there are risks of serious side effects from the cell infusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA

Contacts and locations

Locations

Fudan University
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.